Companies Corcept Therapeutics Inc

Corcept Therapeutics (CORT): executive pay, fiscal 2025

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Corcept Therapeutics Inc’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$15,303,551CEO Joseph Belanoff · source

Say-on-pay support94.08%Latest vote · source

CEO pay ratio46:1To the median employee · source

CEO pay, last three years

$9,337,734FY2023
$9,890,081FY2024
$15,303,551FY2025

CEO total pay was $15,303,551 in fiscal 2025, up from $9,890,081 in fiscal 2024.

FY2025: salary $1,182,333 · bonus $1,190,000 · stock awards $0 · option awards $12,907,718

Executives and directors

Joseph Belanoff · CEO Atabak Mokari · CFO Charles Robb · Executive Sean Maduck · President William Guyer · Chief Development Officer Daniel N. Swisher Jr · Independent Director David L. Mahoney · Independent Director G. Leonard Baker Jr · Independent Director Gillian M. Cannon · Former director (through FY2025)Gregg Alton · Independent Director James N. Wilson · Chair of the Board Joshua M. Murray · Independent Director Kimberly Park · Independent Director

Frequently asked questions

Who was the highest-paid executive at Corcept Therapeutics Inc in fiscal 2025?

As disclosed, Joseph Belanoff (Chief Executive Officer and President) was the highest-paid executive at Corcept Therapeutics Inc in fiscal 2025, with total compensation of $15,303,551.

What is Corcept Therapeutics Inc's CEO-to-median employee pay ratio?

As disclosed, Corcept Therapeutics Inc's CEO-to-median employee pay ratio was 46:1.

How did shareholders vote on Corcept Therapeutics Inc's executive compensation?

As disclosed, 94.08% of shareholders supported Corcept Therapeutics Inc's executive compensation in the latest say-on-pay vote.

How much does Corcept Therapeutics Inc spend in total on board compensation for fiscal 2025?

As disclosed, Corcept Therapeutics Inc reported total board compensation of $610,397 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Joseph Belanoff	$1,182,333	$1,190,000	$0	$12,907,718	$0	$0	$23,500	$15,303,551
Chief Executive Officer and President
Charles Robb	711,413	358,000	124,500	5,163,087	0	0	23,500	6,380,500
Chief Business Officer and Secretary
William Guyer	706,387	429,600	17,871	5,163,087	0	0	23,500	6,340,445
Chief Development Officer
Sean Maduck	648,860	261,200	111,995	5,163,087	0	0	23,500	6,208,642
President, Corcept Endocrinology
Atabak Mokari	566,347	285,000	97,733	5,163,087	0	0	23,500	6,135,667
Chief Financial Officer and Treasurer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2025 total	FY2024 total	FY2023 total	Δ FY2024→2025
Joseph Belanoff	$15,303,551	$9,890,081	$9,337,734	↑ +5,413,470
Charles Robb	6,380,500	4,138,371	3,956,718	↑ +2,242,129
William Guyer	6,340,445	—	3,856,200	—
Sean Maduck	6,208,642	3,971,171	3,908,931	↑ +2,237,471
Atabak Mokari	6,135,667	3,857,306	3,717,107	↑ +2,278,361

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The company aims to offer competitive compensation that rewards good short-term and long-term performance, aligning executive and stockholder interests. Because drug development takes many years, the largest portion of named executives' compensation consists of option grants with extended vesting periods to reward long-term stockholder value creation.

CEO STI target (% of salary)	NaN%
CEO LTI target (% of salary)	—
Independent consultant	—
Clawback policy	—
Anti-hedging	The company has an insider trading policy that prohibits named executive officers and Board members from engaging in short sales and derivative securities related to the company's stock.
Anti-pledging	—

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Charles Robb	OPTION	2025-02-28	—	—	140,000	—	$5,163,087
Joseph Belanoff	OPTION	2025-02-28	—	—	350,000	—	12,907,718
William Guyer	OPTION	2025-02-28	—	—	140,000	—	5,163,087
Sean Maduck	OPTION	2025-02-28	—	—	140,000	—	5,163,087
Atabak Mokari	OPTION	2025-02-28	—	—	140,000	—	5,163,087

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Charles Robb	$0	$0	$5,163,087	0.0%
Joseph Belanoff	0	0	12,907,718	0.0%
William Guyer	0	0	5,163,087	0.0%
Sean Maduck	0	0	5,163,087	0.0%
Atabak Mokari	0	0	5,163,087	0.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

Executive	Award	Shares unvested	Exercise price	Market value unvested
Atabak Mokari	RSU	178	—	$6,194
Atabak Mokari	RSU	200	—	6,960
Sean Maduck	RSU	205	—	7,134
William Guyer	RSU	224	—	7,795
Charles Robb	RSU	224	—	7,795
Sean Maduck	RSU	228	—	7,934
Atabak Mokari	RSU	232	—	8,074
Charles Robb	RSU	251	—	8,735
Sean Maduck	RSU	266	—	9,257
Charles Robb	RSU	292	—	10,162
Atabak Mokari	RSU	775	—	26,970
Sean Maduck	RSU	888	—	30,902
Charles Robb	RSU	997	—	34,696
William Guyer	Option	4,167	19.26	—
Atabak Mokari	Option	4,167	19.26	—
Sean Maduck	Option	4,167	22.05	—
Sean Maduck	Option	8,334	19.26	—
Charles Robb	Option	8,334	19.26	—
Joseph Belanoff	Option	20,834	19.26	—
William Guyer	Option	58,334	23.06	—
Sean Maduck	Option	58,334	23.06	—
Atabak Mokari	Option	58,334	23.06	—
Charles Robb	Option	58,334	23.06	—
William Guyer	Option	108,334	23.01	—
Sean Maduck	Option	108,334	23.01	—
Atabak Mokari	Option	108,334	23.01	—
Charles Robb	Option	108,334	23.01	—
William Guyer	Option	110,834	60.58	—
Sean Maduck	Option	110,834	60.58	—
Atabak Mokari	Option	110,834	60.58	—
Charles Robb	Option	110,834	60.58	—
Joseph Belanoff	Option	145,834	23.06	—
Joseph Belanoff	Option	270,834	23.01	—
Joseph Belanoff	Option	277,084	60.58	—

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
James N. WilsonIndependent · Board Chair · Nominating/Governance	$122,907	—	$1,170,007	—	$0	$1,292,914
Gregg AltonIndependent · Audit · Compensation	85,000	—	702,004	—	0	787,004
David L. MahoneyIndependent · Audit · Compensation (Chair)	82,500	—	702,004	—	0	784,504
Gillian M. CannonIndependent · Audit · Departed during FY	53,259	—	702,004	—	15,241	770,504
G. Leonard Baker JrIndependent · Compensation · Nominating/Governance	66,000	—	702,004	—	0	768,004
Kimberly ParkIndependent · Audit · Nominating/Governance	62,990	—	702,004	—	0	764,994
Joshua M. MurrayIndependent · Audit	62,500	—	702,004	—	0	764,504
Daniel N. Swisher JrIndependent · Compensation	60,000	—	702,004	—	0	762,004
Joseph K. BelanoffEmployee director	—	—	—	—	—	0

Board fee structure and ownership guideline

Annual cash retainer	$50,000
Annual equity retainer	$15,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	25,000 / 20,000 / 12,000
Stock ownership guideline	—

Total cost of the board

Component	FY2025
Cash retainers and fees	$595,156
Equity awards (grant-date value)	$0
All other compensation	$15,241
Total cost of the board	$610,397

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Corcept Therapeutics as a peer

Companies that benchmark against CORT

23 companies name CORT as a compensation peer

The list of companies that name CORT as a peer is temporarily unavailable — recheck shortly.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	Corcept Therapeutics Inc	2025	Joseph Belanoff	$1,182,333	$0	$12,907,718	$0	$15,303,551

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2026	2026-05-21	72,511,429	4,560,385	222,643	94.08%	Passed
2025	2025-06-10	72,914,293	4,195,859	284,923	94.56%	Passed
2024	2024-05-17	64,501,372	1,018,089	358,666	98.45%	Passed
2023	2023-05-19	69,095,025	1,450,799	235,570	97.62%	Passed
2020	2020-05-27	76,887,975	5,808,900	305,179	92.98%	Passed
2017	2017-05-24	75,561,267	4,089,353	93,419	94.87%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2026	2026-05-21	94.08%^a
2025	2025-06-10	94.56%^b
2024	2024-05-17	98.45%^c

a. Approved under the standard stated in the filing — “any shares abstained from voting " FOR " a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be counted in such nominee's favor and will have no effect on the outcome of the election.”.

b. Approved under the standard stated in the filing — “any shares abstained from voting " FOR " a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be counted in such nominee's favor and will have no effect on the outcome of the election.”.

c. Approved under the standard stated in the filing — “As a result, only " FOR " votes will affect the outcome, and any shares abstained from voting " FOR " a particular nominee (whether as a result of stockholder abstention or a broker non-vote) will not be counted in such nominee's favor and will have no effect on the outcome of the election.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)	46 : 1
CEO total compensation	$15,303,551
Median employee compensation	$334,040

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Charles Robb	Chief Business Officer	2026-05-13	A	1,000	$0	$0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-05-13	D	5,300	0	0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-05-13	A	1,000	0	0	Common	Form 4 ↗
Joshua M. Murray	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
Daniel N. Swisher Jr	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
James N. Wilson	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
Gregg Alton	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
G. Leonard Baker Jr	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
David L. Mahoney	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
Kimberly Park	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
James N. Wilson	Director	2026-05-27	A	9,011	0	0	Common, indirect	Form 4 ↗
Charles Robb	Chief Business Officer	2026-05-27	D	600	0	0	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-05-27	A	75,000	8	620,250	Common	Form 4 ↗
James N. Wilson	Director	2026-05-27	D	9,011	0	0	Common, indirect	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-05-27	D	5,000	65	325,000	Common	Form 4 ↗
James N. Wilson	Director	2026-05-27	D	892,056	0	0	Common, indirect	Form 4 ↗
Sean Maduck	See Remarks	2026-05-27	D	75,000	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-05-27	D	54,575	65	3,567,628	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-05-27	D	20,425	66	1,351,316	Common, open-market sale	Form 4 ↗
Joseph K. Belanoff	Director	2026-05-29	A	150,000	0	0	Common	Form 4 ↗
Joseph K. Belanoff	Director	2026-05-29	A	150,000	0	0	Common	Form 4 ↗
Joseph K. Belanoff	Director	2026-05-29	D	300,000	0	0	Common, indirect	Form 4 ↗
Joseph K. Belanoff	Director	2026-06-01	D	12,837	70	895,252	Common, indirect	Form 4 ↗
Charles Robb	Chief Business Officer	2026-06-01	A	776	0	0	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-01	A	634	70	44,659	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-01	A	40,000	19	770,400	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	D	3,931	71	278,103	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-01	D	40,000	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	D	25,000	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	A	25,000	8	206,750	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-06-01	A	877	0	0	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-06-01	A	537	0	0	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-01	A	634	0	0	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-01	D	40,000	70	2,800,004	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	D	21,069	70	1,477,080	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-06-01	A	537	70	37,826	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-06-01	A	776	70	54,661	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	A	615	0	0	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	A	615	70	43,321	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-06-01	A	877	70	61,776	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-02	D	395	70	27,824	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-02	D	452	70	31,839	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-06-02	D	20,000	0	0	Derivative, Class A Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-06-02	D	358	70	25,218	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-06-02	D	269	70	18,948	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-06-02	D	20,000	71	1,412,000	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-06-02	A	20,000	22	433,000	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	D	40,000	0	0	Derivative, Class A Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	D	2	82	165	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	D	11,081	81	896,923	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	D	9,434	80	754,924	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	D	19,483	82	1,593,889	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	A	40,000	19	770,400	Common	Form 4 ↗
James N. Wilson	Director	2026-06-16	D	4,177	83	345,416	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-06-16	D	5,823	84	486,633	Common, indirect	Form 4 ↗
David L. Mahoney	Director	2026-06-17	D	20,000	85	1,690,506	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-07-01	D	2,801	89	247,924	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-07-01	D	11,024	87	962,780	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-07-01	A	25,000	8	206,750	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-07-01	D	25,000	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-07-01	D	11,175	89	998,033	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-07-07	D	19,048	93	1,773,481	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-07-07	A	20,000	22	433,000	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-07-07	D	20,000	0	0	Derivative, Class A Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-07-07	D	952	94	89,048	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	24,167	0	0	Derivative, Class A Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	101	89	9,032	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	3,520	88	310,822	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	28,460	88	2,501,244	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	A	24,167	23	557,291	Common	Form 4 ↗
James N. Wilson	Director	2026-07-15	D	1,978	89	177,007	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-07-15	D	1,079	87	93,633	Common, indirect	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	15,833	0	0	Derivative, Class A Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	7,919	87	687,179	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	A	15,833	19	304,944	Common	Form 4 ↗
James N. Wilson	Director	2026-07-15	D	2,974	89	264,122	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-07-15	D	3,969	88	348,223	Common, indirect	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	8,267	118	974,951	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	80,000	0	0	Derivative, Class A Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	1,001	121	120,796	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	14,222	116	1,647,859	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	15,477	115	1,779,237	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	600	111	66,570	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	8,956	107	957,892	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	A	80,000	23	1,844,800	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	8,103	120	971,939	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	4,700	113	531,941	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	400	108	43,384	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	4,783	119	567,908	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	7,089	117	829,102	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	2,202	110	242,282	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	4,200	106	443,248	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-08-03	D	1,540	114	175,806	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-03	D	20,305	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-03	D	20,305	115	2,329,075	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-08-03	A	20,305	8	167,922	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-04	A	3,700	22	80,105	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-04	D	3,700	0	0	Derivative, Class A Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-04	D	3,700	113	418,562	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-10	D	11,530	113	1,304,933	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-10	A	16,300	22	352,895	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-10	D	1,031	115	118,068	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-08-10	A	1,031	8	8,526	Common	Form 4 ↗
Dividend-equivalent accruals		2026-08-10	—	1,031	—	—	1 insider, 1 accrual row
William Guyer	Chief Development Officer	2026-08-10	D	16,300	0	0	Derivative, Class A Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-10	D	4,770	114	543,957	Common, open-market sale	Form 4 ↗
Charles Robb	Chief Business Officer	2026-08-12	A	3,000	0	0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-08-12	D	11,530	0	0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-08-12	A	3,000	0	0	Common	Form 4 ↗
James N. Wilson	Director	2026-08-14	D	4,668	111	520,214	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-08-14	D	3,053	110	337,341	Common, indirect	Form 4 ↗
Sean Maduck	See Remarks	2026-08-14	D	3,664	114	419,491	Common	Form 4 ↗
James N. Wilson	Director	2026-08-14	D	2,279	113	256,706	Common, indirect	Form 4 ↗
Sean Maduck	See Remarks	2026-08-14	A	3,664	8	30,301	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-14	D	3,664	0	0	Derivative, Class A Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-08-17	D	10,000	116	1,162,572	Common, open-market sale	Form 4 ↗
Charles Robb	Chief Business Officer	2026-08-17	D	125	0	0	Common	Form 4 ↗
David L. Mahoney	Director	2026-08-18	D	400	120	47,855	Common, open-market sale	Form 4 ↗
David L. Mahoney	Director	2026-08-18	D	7,055	119	838,710	Common, open-market sale	Form 4 ↗
David L. Mahoney	Director	2026-08-18	D	4,984	117	585,478	Common, open-market sale	Form 4 ↗
David L. Mahoney	Director	2026-08-18	D	91,167	118	10,779,367	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-08-25	D	30,955	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-25	A	30,955	11	351,339	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-25	D	5,870	126	739,965	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-08-25	D	25,085	125	3,147,355	Common, open-market sale	Form 4 ↗
Kimberly Park	Director	2026-08-26	D	30,000	0	0	Derivative, Class A Common	Form 4 ↗
Kimberly Park	Director	2026-08-26	D	26,685	123	3,270,169	Common, open-market sale	Form 4 ↗
Kimberly Park	Director	2026-08-26	D	3,315	122	404,728	Common	Form 4 ↗
Kimberly Park	Director	2026-08-26	A	30,000	13	404,700	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-01	A	130	0	0	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-01	A	130	113	14,739	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-01	A	138	0	0	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-01	A	138	113	15,646	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-01	A	164	113	18,594	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-09-01	A	138	0	0	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	D	25,000	0	0	Derivative, Class A Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-09-01	A	138	113	15,646	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	A	150	0	0	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	A	25,000	8	206,750	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-09-01	A	164	113	18,594	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	D	2,281	116	263,711	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	D	10,989	115	1,260,568	Common, open-market sale	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-01	A	164	0	0	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	A	150	113	17,007	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	D	11,730	114	1,336,459	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-09-01	A	164	0	0	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	58,333	0	0	Derivative, Class A Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	23,600	109	2,580,674	Common, open-market sale	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-02	D	91	113	10,318	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	23,770	111	2,631,349	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	102	113	11,565	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	1,537	111	171,181	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-02	D	72	113	8,163	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	5,621	115	644,042	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	1,606	114	182,632	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	974	112	109,474	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	A	58,333	22	1,261,743	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-09-02	D	102	113	11,565	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-02	D	117	113	13,265	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	1,225	115	141,413	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	D	2,596	0	0	Derivative, Class A Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	A	2,596	11	29,465	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	D	2,188	114	249,686	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	A	7,404	14	100,398	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	D	7,404	0	0	Derivative, Class A Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	D	7,812	113	885,261	Common, open-market sale	Form 4 ↗
James N. Wilson	Director	2026-09-15	D	6,800	110	749,835	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-09-15	D	400	111	44,335	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-09-15	D	2,800	112	312,771	Common, indirect	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-16	D	296	101	29,843	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-17	A	17,493	8	144,667	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-17	D	17,493	0	0	Derivative, Class A Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-24	A	5,000	0	0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-24	A	5,000	0	0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-24	D	17,100	0	0	Common	Form 4 ↗
Dividend-equivalent accruals		2026-10-01	—	1,223	—	—	2 insiders, 2 accrual rows
Sean Maduck	See Remarks	2026-10-01	A	413	8	3,416	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-01	D	810	115	93,473	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-01	A	810	14	10,984	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-10-01	D	413	116	47,717	Common, open-market sale	Form 4 ↗
Justin Frederick Gunn	See Remarks	2026-10-01	A	100,000	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-10-02	D	24,587	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-10-02	D	8,744	117	1,019,143	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-10-02	D	15,843	116	1,839,741	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-10-02	A	24,587	8	203,334	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-10-02	D	8,333	0	0	Derivative, Class A Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-10-02	D	5,147	117	600,063	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-10-02	D	2,086	116	241,412	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-10-02	D	1,100	115	125,973	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-10-02	A	8,333	22	180,243	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	D	5,833	0	0	Derivative, Class A Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	D	3,357	0	0	Derivative, Class A Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	D	4,744	117	552,869	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	D	4,446	116	514,389	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	A	5,833	19	112,344	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	A	3,357	14	45,521	Common	Form 4 ↗
James N. Wilson	Director	2026-10-15	D	300	116	34,889	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-10-15	D	3,046	115	351,476	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-10-15	D	6,654	114	761,717	Common, indirect	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 200 transactions

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Charles Robb	Chief Business Officer	2026-05-13	A	1,000	$0	$0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-05-13	D	5,300	0	0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-05-13	A	1,000	0	0	Common	Form 4 ↗
Joshua M. Murray	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
Daniel N. Swisher Jr	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
James N. Wilson	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
Gregg Alton	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
G. Leonard Baker Jr	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
David L. Mahoney	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
Kimberly Park	Director	2026-05-21	A	12,500	0	0	Derivative, Class A Common	Form 4 ↗
James N. Wilson	Director	2026-05-27	A	9,011	0	0	Common, indirect	Form 4 ↗
Charles Robb	Chief Business Officer	2026-05-27	D	600	0	0	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-05-27	A	75,000	8	620,250	Common	Form 4 ↗
James N. Wilson	Director	2026-05-27	D	9,011	0	0	Common, indirect	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-05-27	D	5,000	65	325,000	Common	Form 4 ↗
James N. Wilson	Director	2026-05-27	D	892,056	0	0	Common, indirect	Form 4 ↗
Sean Maduck	See Remarks	2026-05-27	D	75,000	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-05-27	D	54,575	65	3,567,628	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-05-27	D	20,425	66	1,351,316	Common, open-market sale	Form 4 ↗
Joseph K. Belanoff	Director	2026-05-29	A	150,000	0	0	Common	Form 4 ↗
Joseph K. Belanoff	Director	2026-05-29	A	150,000	0	0	Common	Form 4 ↗
Joseph K. Belanoff	Director	2026-05-29	D	300,000	0	0	Common, indirect	Form 4 ↗
Joseph K. Belanoff	Director	2026-06-01	D	12,837	70	895,252	Common, indirect	Form 4 ↗
Charles Robb	Chief Business Officer	2026-06-01	A	776	0	0	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-01	A	634	70	44,659	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-01	A	40,000	19	770,400	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	D	3,931	71	278,103	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-01	D	40,000	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	D	25,000	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	A	25,000	8	206,750	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-06-01	A	877	0	0	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-06-01	A	537	0	0	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-01	A	634	0	0	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-01	D	40,000	70	2,800,004	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	D	21,069	70	1,477,080	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-06-01	A	537	70	37,826	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-06-01	A	776	70	54,661	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	A	615	0	0	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-01	A	615	70	43,321	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-06-01	A	877	70	61,776	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-02	D	395	70	27,824	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-06-02	D	452	70	31,839	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-06-02	D	20,000	0	0	Derivative, Class A Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-06-02	D	358	70	25,218	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-06-02	D	269	70	18,948	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-06-02	D	20,000	71	1,412,000	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-06-02	A	20,000	22	433,000	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	D	40,000	0	0	Derivative, Class A Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	D	2	82	165	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	D	11,081	81	896,923	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	D	9,434	80	754,924	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	D	19,483	82	1,593,889	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-06-15	A	40,000	19	770,400	Common	Form 4 ↗
James N. Wilson	Director	2026-06-16	D	4,177	83	345,416	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-06-16	D	5,823	84	486,633	Common, indirect	Form 4 ↗
David L. Mahoney	Director	2026-06-17	D	20,000	85	1,690,506	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-07-01	D	2,801	89	247,924	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-07-01	D	11,024	87	962,780	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-07-01	A	25,000	8	206,750	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-07-01	D	25,000	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-07-01	D	11,175	89	998,033	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-07-07	D	19,048	93	1,773,481	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-07-07	A	20,000	22	433,000	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-07-07	D	20,000	0	0	Derivative, Class A Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-07-07	D	952	94	89,048	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	24,167	0	0	Derivative, Class A Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	101	89	9,032	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	3,520	88	310,822	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	28,460	88	2,501,244	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	A	24,167	23	557,291	Common	Form 4 ↗
James N. Wilson	Director	2026-07-15	D	1,978	89	177,007	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-07-15	D	1,079	87	93,633	Common, indirect	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	15,833	0	0	Derivative, Class A Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	D	7,919	87	687,179	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-15	A	15,833	19	304,944	Common	Form 4 ↗
James N. Wilson	Director	2026-07-15	D	2,974	89	264,122	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-07-15	D	3,969	88	348,223	Common, indirect	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	8,267	118	974,951	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	80,000	0	0	Derivative, Class A Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	1,001	121	120,796	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	14,222	116	1,647,859	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	15,477	115	1,779,237	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	600	111	66,570	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	8,956	107	957,892	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	A	80,000	23	1,844,800	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	8,103	120	971,939	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	4,700	113	531,941	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	400	108	43,384	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	4,783	119	567,908	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	7,089	117	829,102	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	2,202	110	242,282	Common, open-market sale	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-07-30	D	4,200	106	443,248	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-08-03	D	1,540	114	175,806	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-03	D	20,305	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-03	D	20,305	115	2,329,075	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-08-03	A	20,305	8	167,922	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-04	A	3,700	22	80,105	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-04	D	3,700	0	0	Derivative, Class A Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-04	D	3,700	113	418,562	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-10	D	11,530	113	1,304,933	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-10	A	16,300	22	352,895	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-10	D	1,031	115	118,068	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-08-10	A	1,031	8	8,526	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-10	D	1,031	0	0	Derivative, Class A Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-10	D	16,300	0	0	Derivative, Class A Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-08-10	D	4,770	114	543,957	Common, open-market sale	Form 4 ↗
Charles Robb	Chief Business Officer	2026-08-12	A	3,000	0	0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-08-12	D	11,530	0	0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-08-12	A	3,000	0	0	Common	Form 4 ↗
James N. Wilson	Director	2026-08-14	D	4,668	111	520,214	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-08-14	D	3,053	110	337,341	Common, indirect	Form 4 ↗
Sean Maduck	See Remarks	2026-08-14	D	3,664	114	419,491	Common	Form 4 ↗
James N. Wilson	Director	2026-08-14	D	2,279	113	256,706	Common, indirect	Form 4 ↗
Sean Maduck	See Remarks	2026-08-14	A	3,664	8	30,301	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-14	D	3,664	0	0	Derivative, Class A Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-08-17	D	10,000	116	1,162,572	Common, open-market sale	Form 4 ↗
Charles Robb	Chief Business Officer	2026-08-17	D	125	0	0	Common	Form 4 ↗
David L. Mahoney	Director	2026-08-18	D	400	120	47,855	Common, open-market sale	Form 4 ↗
David L. Mahoney	Director	2026-08-18	D	7,055	119	838,710	Common, open-market sale	Form 4 ↗
David L. Mahoney	Director	2026-08-18	D	4,984	117	585,478	Common, open-market sale	Form 4 ↗
David L. Mahoney	Director	2026-08-18	D	91,167	118	10,779,367	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-08-25	D	30,955	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-25	A	30,955	11	351,339	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-08-25	D	5,870	126	739,965	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-08-25	D	25,085	125	3,147,355	Common, open-market sale	Form 4 ↗
Kimberly Park	Director	2026-08-26	D	30,000	0	0	Derivative, Class A Common	Form 4 ↗
Kimberly Park	Director	2026-08-26	D	26,685	123	3,270,169	Common, open-market sale	Form 4 ↗
Kimberly Park	Director	2026-08-26	D	3,315	122	404,728	Common	Form 4 ↗
Kimberly Park	Director	2026-08-26	A	30,000	13	404,700	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-01	A	130	0	0	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-01	A	130	113	14,739	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-01	A	138	0	0	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-01	A	138	113	15,646	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-01	A	164	113	18,594	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-09-01	A	138	0	0	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	D	25,000	0	0	Derivative, Class A Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-09-01	A	138	113	15,646	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	A	150	0	0	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	A	25,000	8	206,750	Common	Form 4 ↗
William Guyer	Chief Development Officer	2026-09-01	A	164	113	18,594	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	D	2,281	116	263,711	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	D	10,989	115	1,260,568	Common, open-market sale	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-01	A	164	0	0	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	A	150	113	17,007	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-01	D	11,730	114	1,336,459	Common, open-market sale	Form 4 ↗
William Guyer	Chief Development Officer	2026-09-01	A	164	0	0	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	58,333	0	0	Derivative, Class A Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	23,600	109	2,580,674	Common, open-market sale	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-02	D	91	113	10,318	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	23,770	111	2,631,349	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	102	113	11,565	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	1,537	111	171,181	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-02	D	72	113	8,163	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	5,621	115	644,042	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	1,606	114	182,632	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	974	112	109,474	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	A	58,333	22	1,261,743	Common	Form 4 ↗
Atabak Mokari	Chief Financial Officer	2026-09-02	D	102	113	11,565	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-09-02	D	117	113	13,265	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-02	D	1,225	115	141,413	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	D	2,596	0	0	Derivative, Class A Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	A	2,596	11	29,465	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	D	2,188	114	249,686	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	A	7,404	14	100,398	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	D	7,404	0	0	Derivative, Class A Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-09-14	D	7,812	113	885,261	Common, open-market sale	Form 4 ↗
James N. Wilson	Director	2026-09-15	D	6,800	110	749,835	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-09-15	D	400	111	44,335	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-09-15	D	2,800	112	312,771	Common, indirect	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-09-16	D	296	101	29,843	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-17	A	17,493	8	144,667	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-17	D	17,493	0	0	Derivative, Class A Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-24	A	5,000	0	0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-24	A	5,000	0	0	Common	Form 4 ↗
Charles Robb	Chief Business Officer	2026-09-24	D	17,100	0	0	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-10-01	D	413	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-10-01	A	413	8	3,416	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-01	D	810	0	0	Derivative, Class A Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-01	D	810	115	93,473	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-01	A	810	14	10,984	Common	Form 4 ↗
Sean Maduck	See Remarks	2026-10-01	D	413	116	47,717	Common, open-market sale	Form 4 ↗
Justin Frederick Gunn	See Remarks	2026-10-01	A	100,000	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-10-02	D	24,587	0	0	Derivative, Class A Common	Form 4 ↗
Sean Maduck	See Remarks	2026-10-02	D	8,744	117	1,019,143	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-10-02	D	15,843	116	1,839,741	Common, open-market sale	Form 4 ↗
Sean Maduck	See Remarks	2026-10-02	A	24,587	8	203,334	Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-10-02	D	8,333	0	0	Derivative, Class A Common	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-10-02	D	5,147	117	600,063	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-10-02	D	2,086	116	241,412	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-10-02	D	1,100	115	125,973	Common, open-market sale	Form 4 ↗
Roberto Wandenkolk Vieira	President, Oncology	2026-10-02	A	8,333	22	180,243	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	D	5,833	0	0	Derivative, Class A Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	D	3,357	0	0	Derivative, Class A Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	D	4,744	117	552,869	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	D	4,446	116	514,389	Common, open-market sale	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	A	5,833	19	112,344	Common	Form 4 ↗
Joseph Douglas Lyon	See Remarks	2026-10-02	A	3,357	14	45,521	Common	Form 4 ↗
James N. Wilson	Director	2026-10-15	D	300	116	34,889	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-10-15	D	3,046	115	351,476	Common, indirect	Form 4 ↗
James N. Wilson	Director	2026-10-15	D	6,654	114	761,717	Common, indirect	Form 4 ↗

Sources (227 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Joseph Belanoff. DEF 14A, filed 2026-04-17. Section “Executive Compensation” · page 19. As printed: 15,303,551. View filing ↗
Section 01, Charles Robb. DEF 14A, filed 2026-04-17. Section “Executive Compensation”. As printed: 6,380,500. View filing ↗
Section 01, William Guyer. DEF 14A, filed 2026-04-17. Section “Executive Compensation”. As printed: 6,340,445. View filing ↗
Section 01, Sean Maduck. DEF 14A, filed 2026-04-17. Section “Executive Compensation”. As printed: 6,208,642. View filing ↗
Section 01, Atabak Mokari. DEF 14A, filed 2026-04-17. Section “Executive Compensation”. As printed: 6,135,667. View filing ↗
Section 03, Charles Robb OPTION. DEF 14A, filed 2026-04-17. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Joseph Belanoff OPTION. DEF 14A, filed 2026-04-17. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, William Guyer OPTION. DEF 14A, filed 2026-04-17. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Sean Maduck OPTION. DEF 14A, filed 2026-04-17. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 03, Atabak Mokari OPTION. DEF 14A, filed 2026-04-17. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
Section 07, pay ratio. DEF 14A, filed 2026-04-17. Section “CEO Pay Ratio”. As printed: 46 : 1. View filing ↗
Section 08, James N. Wilson. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 1,292,914. View filing ↗
Section 08, Gregg Alton. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 787,004. View filing ↗
Section 08, David L. Mahoney. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 784,504. View filing ↗
Section 08, Gillian M. Cannon. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 770,504. View filing ↗
Section 08, G. Leonard Baker Jr. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 768,004. View filing ↗
Section 08, Kimberly Park. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 764,994. View filing ↗
Section 08, Joshua M. Murray. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 764,504. View filing ↗
Section 08, Daniel N. Swisher Jr. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 762,004. View filing ↗
Section 08, Joseph K. Belanoff. DEF 14A, filed 2026-04-17. Section “Director Compensation”. As printed: 0. View filing ↗
Section 02, Charles Robb 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-05-13. Form 4, filed 2026-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joshua M. Murray 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Daniel N. Swisher Jr 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gregg Alton 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, G. Leonard Baker Jr 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David L. Mahoney 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kimberly Park 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-05-27. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-05-27. Form 4, filed 2026-05-29. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph K. Belanoff 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph K. Belanoff 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph K. Belanoff 2026-05-29. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph K. Belanoff 2026-06-01. Form 4, filed 2026-06-02. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-06-01. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-06-02. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-06-02. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-06-02. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-06-02. Form 4, filed 2026-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-06-16. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David L. Mahoney 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-07-01. Form 4, filed 2026-07-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-07-07. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-07-07. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-07-07. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-07-07. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-07-15. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-08-12. Form 4, filed 2026-08-14. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-08-14. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-08-14. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-14. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-08-14. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-14. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-14. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-08-17. Form 4, filed 2026-08-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David L. Mahoney 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David L. Mahoney 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David L. Mahoney 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David L. Mahoney 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-25. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-25. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-25. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-08-25. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kimberly Park 2026-08-26. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kimberly Park 2026-08-26. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kimberly Park 2026-08-26. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Kimberly Park 2026-08-26. Form 4, filed 2026-08-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, William Guyer 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Atabak Mokari 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-09-15. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-09-16. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-09-17. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-09-17. Form 4, filed 2026-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-09-24. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-09-24. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Robb 2026-09-24. Form 4, filed 2026-09-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Justin Frederick Gunn 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Sean Maduck 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Roberto Wandenkolk Vieira 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph Douglas Lyon 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, James N. Wilson 2026-10-15. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2026 vote. Form 8-K, filed 2026-05-28. Item 5.07 · say-on-pay result. As reported: 94.08% (votes for as printed: 72,511,429). View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-06-16. Item 5.07 · say-on-pay result. As reported: 94.56% (votes for as printed: 72,914,293). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-05-23. Item 5.07 · say-on-pay result. As reported: 98.45% (votes for as printed: 64,501,372). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 595,156 + equity 0 + all other 15,241 = 610,397, summed across the director compensation table rows.
Corcept Therapeutics Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics Inc's own proxy. As printed: 15,303,551. View filing ↗